Johnson & Johnson announced the submission of two supplemental Biologics License Applications to the FDA seeking approval of TREMFYA for the treatment of children 6 years and older with moderate-to-severe plaque psoriasis and children 5 years of age and older with active juvenile psoriatic arthritis.
Liza O'Dowd, Vice President, Immunodermatology Disease Area Leader, Johnson & Johnson Innovative Medicine, said: "There is a critical gap in the treatment of children and adolescents with these skin and joint conditions, where debilitating symptoms can present challenges related to physical appearance and ability to function."
TREMFYA is the first approved monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.